• Zhong Ning Leonard Goh, Roland Yii Lin Teo, Bui Khiong Chung, Alexis Ching Wong, and Chen-June Seak.
• Department of Medicine, Sarawak General Hospital, Ministry of Health, Kuching, Sarawak, Malaysia.
• Medicine (Baltimore). 2022 Aug 5; 101 (31): e29951e29951.

AbstractHeart failure leading to cardiac ascites is an extremely rare and underrecognized entity in clinical practice. Recognizing cardiac ascites can be difficult, especially since patients presenting with ascites may have more than 1 etiology. Various biomarkers are available to aid in the diagnosis of cardiac ascites, though with differing sensitivities and specificities. Such biomarkers include serum albumin, ascitic albumin and protein, as well as serum N-terminal pro-brain natriuretic peptide (NT-proBNP). While serum NT-proBNP is a powerful biomarker in distinguishing the etiology of ascites and monitoring treatment progression, its cost can be prohibitive in low-resource settings. Clinicians practicing under these circumstances may opt to rely on other parameters to manage their patients. We go on further to report a series of 3 patients with cardiac ascites to illustrate how these biomarkers may be employed in the management of this patient population. Clinicians should always keep in mind the differential diagnosis of cardiac failure as a cause of ascites. The resolution of cardiac ascites may serve as a surrogate clinical marker for response to antifailure therapy in lieu of NT-proBNP at resource-scarce centers.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

24 keywords...

hide…